Medication Effects on EEG Biomarkers in Attention-Deficit/Hyperactivity Disorder
EEG biomarkers have become increasingly used to aid in diagnosis of attention-deficit/hyperactivity disorder (ADHD). Despite several studies suggesting that EEG theta/beta ratio may help discriminating ADHD from other disorders, the effect of medications on theta/beta ratio is not known. Forty-three...
Gespeichert in:
| Veröffentlicht in: | Clinical EEG and neuroscience 2017-07, Vol.48 (4), p.246-250 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 250 |
|---|---|
| container_issue | 4 |
| container_start_page | 246 |
| container_title | Clinical EEG and neuroscience |
| container_volume | 48 |
| creator | Isiten, Havva Nuket Cebi, Merve Sutcubasi Kaya, Bernis Metin, Baris Tarhan, Nevzat |
| description | EEG biomarkers have become increasingly used to aid in diagnosis of attention-deficit/hyperactivity disorder (ADHD). Despite several studies suggesting that EEG theta/beta ratio may help discriminating ADHD from other disorders, the effect of medications on theta/beta ratio is not known. Forty-three children with ADHD that were evaluated with quantitative EEG before and after methylphenidate were included in the study. Theta/beta ratio, theta and beta powers for whole brain, central, and frontal areas were calculated. Theta/beta power decreased significantly after treatment; however, this change was largely due to an increase in beta power, rather than a fall in theta power. The results suggest that beta power is sensitive to medication effects, while theta power remains as a trait biomarker unaffected by medication status. The value of EEG biomarkers for monitoring neuropsychological performance and clinical status should be explored by future studies. |
| doi_str_mv | 10.1177/1550059416675232 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1834998420</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1550059416675232</sage_id><sourcerecordid>1910433388</sourcerecordid><originalsourceid>FETCH-LOGICAL-c431t-aa04f1288e7fa4a4707779dc358c7a99f841d2a844e5f6720a5fd9e5660335273</originalsourceid><addsrcrecordid>eNp1kM1LAzEQxYMotlbvnmTBi5e1-dwkx6q1FSp60PMSsxNJbXdrkgr9792lVaTgaQbm9948HkLnBF8TIuWQCIGx0JwUhRSU0QPUp6TQuaCYHqJ-d867ew-dxDjHmBWU8WPUo1JqRTXuo-dHqLw1yTd1NnYObIpZt44n2Y1vliZ8QIiZr7NRSlB3WH4HzlufhtPNCoKxyX_5tMnufGxCBeEUHTmziHC2mwP0ej9-uZ3ms6fJw-1ollvOSMqNwdwRqhRIZ7jhEss2U2WZUFYarZ3ipKJGcQ7CFZJiI1ylQRQFZkxQyQboauu7Cs3nGmIqlz5aWCxMDc06lkQxrrXiFLfo5R46b9ahbtOVRBPMGWNKtRTeUjY0MQZw5Sr4toBNSXDZtV3ut91KLnbG67clVL-Cn3pbIN8C0bzDn6__GX4DXyaEvA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1910433388</pqid></control><display><type>article</type><title>Medication Effects on EEG Biomarkers in Attention-Deficit/Hyperactivity Disorder</title><source>MEDLINE</source><source>SAGE Complete</source><creator>Isiten, Havva Nuket ; Cebi, Merve ; Sutcubasi Kaya, Bernis ; Metin, Baris ; Tarhan, Nevzat</creator><creatorcontrib>Isiten, Havva Nuket ; Cebi, Merve ; Sutcubasi Kaya, Bernis ; Metin, Baris ; Tarhan, Nevzat</creatorcontrib><description>EEG biomarkers have become increasingly used to aid in diagnosis of attention-deficit/hyperactivity disorder (ADHD). Despite several studies suggesting that EEG theta/beta ratio may help discriminating ADHD from other disorders, the effect of medications on theta/beta ratio is not known. Forty-three children with ADHD that were evaluated with quantitative EEG before and after methylphenidate were included in the study. Theta/beta ratio, theta and beta powers for whole brain, central, and frontal areas were calculated. Theta/beta power decreased significantly after treatment; however, this change was largely due to an increase in beta power, rather than a fall in theta power. The results suggest that beta power is sensitive to medication effects, while theta power remains as a trait biomarker unaffected by medication status. The value of EEG biomarkers for monitoring neuropsychological performance and clinical status should be explored by future studies.</description><identifier>ISSN: 1550-0594</identifier><identifier>EISSN: 2169-5202</identifier><identifier>DOI: 10.1177/1550059416675232</identifier><identifier>PMID: 27798290</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Adolescent ; Antidepressive Agents - administration & dosage ; Attention Deficit Disorder with Hyperactivity - diagnosis ; Attention Deficit Disorder with Hyperactivity - drug therapy ; Attention Deficit Disorder with Hyperactivity - physiopathology ; Attention deficit hyperactivity disorder ; Bioindicators ; Biomarkers ; Brain ; Brain Waves - drug effects ; Central Nervous System Stimulants - administration & dosage ; Child ; Children ; Comorbidity ; Dextroamphetamine - administration & dosage ; Dopamine ; Dopamine Antagonists - administration & dosage ; Drug Monitoring ; EEG ; Electroencephalography ; Electroencephalography - drug effects ; Electroencephalography - methods ; Female ; Humans ; Hyperactivity ; Male ; Medical imaging ; Methylphenidate ; Methylphenidate - administration & dosage ; Neurosciences ; Observer Variation ; Psychiatry ; Reproducibility of Results ; Retrospective Studies ; Sensitivity and Specificity ; Studies ; Treatment Outcome</subject><ispartof>Clinical EEG and neuroscience, 2017-07, Vol.48 (4), p.246-250</ispartof><rights>EEG and Clinical Neuroscience Society (ECNS) 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c431t-aa04f1288e7fa4a4707779dc358c7a99f841d2a844e5f6720a5fd9e5660335273</citedby><cites>FETCH-LOGICAL-c431t-aa04f1288e7fa4a4707779dc358c7a99f841d2a844e5f6720a5fd9e5660335273</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1550059416675232$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1550059416675232$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27798290$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Isiten, Havva Nuket</creatorcontrib><creatorcontrib>Cebi, Merve</creatorcontrib><creatorcontrib>Sutcubasi Kaya, Bernis</creatorcontrib><creatorcontrib>Metin, Baris</creatorcontrib><creatorcontrib>Tarhan, Nevzat</creatorcontrib><title>Medication Effects on EEG Biomarkers in Attention-Deficit/Hyperactivity Disorder</title><title>Clinical EEG and neuroscience</title><addtitle>Clin EEG Neurosci</addtitle><description>EEG biomarkers have become increasingly used to aid in diagnosis of attention-deficit/hyperactivity disorder (ADHD). Despite several studies suggesting that EEG theta/beta ratio may help discriminating ADHD from other disorders, the effect of medications on theta/beta ratio is not known. Forty-three children with ADHD that were evaluated with quantitative EEG before and after methylphenidate were included in the study. Theta/beta ratio, theta and beta powers for whole brain, central, and frontal areas were calculated. Theta/beta power decreased significantly after treatment; however, this change was largely due to an increase in beta power, rather than a fall in theta power. The results suggest that beta power is sensitive to medication effects, while theta power remains as a trait biomarker unaffected by medication status. The value of EEG biomarkers for monitoring neuropsychological performance and clinical status should be explored by future studies.</description><subject>Adolescent</subject><subject>Antidepressive Agents - administration & dosage</subject><subject>Attention Deficit Disorder with Hyperactivity - diagnosis</subject><subject>Attention Deficit Disorder with Hyperactivity - drug therapy</subject><subject>Attention Deficit Disorder with Hyperactivity - physiopathology</subject><subject>Attention deficit hyperactivity disorder</subject><subject>Bioindicators</subject><subject>Biomarkers</subject><subject>Brain</subject><subject>Brain Waves - drug effects</subject><subject>Central Nervous System Stimulants - administration & dosage</subject><subject>Child</subject><subject>Children</subject><subject>Comorbidity</subject><subject>Dextroamphetamine - administration & dosage</subject><subject>Dopamine</subject><subject>Dopamine Antagonists - administration & dosage</subject><subject>Drug Monitoring</subject><subject>EEG</subject><subject>Electroencephalography</subject><subject>Electroencephalography - drug effects</subject><subject>Electroencephalography - methods</subject><subject>Female</subject><subject>Humans</subject><subject>Hyperactivity</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Methylphenidate</subject><subject>Methylphenidate - administration & dosage</subject><subject>Neurosciences</subject><subject>Observer Variation</subject><subject>Psychiatry</subject><subject>Reproducibility of Results</subject><subject>Retrospective Studies</subject><subject>Sensitivity and Specificity</subject><subject>Studies</subject><subject>Treatment Outcome</subject><issn>1550-0594</issn><issn>2169-5202</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kM1LAzEQxYMotlbvnmTBi5e1-dwkx6q1FSp60PMSsxNJbXdrkgr9792lVaTgaQbm9948HkLnBF8TIuWQCIGx0JwUhRSU0QPUp6TQuaCYHqJ-d867ew-dxDjHmBWU8WPUo1JqRTXuo-dHqLw1yTd1NnYObIpZt44n2Y1vliZ8QIiZr7NRSlB3WH4HzlufhtPNCoKxyX_5tMnufGxCBeEUHTmziHC2mwP0ej9-uZ3ms6fJw-1ollvOSMqNwdwRqhRIZ7jhEss2U2WZUFYarZ3ipKJGcQ7CFZJiI1ylQRQFZkxQyQboauu7Cs3nGmIqlz5aWCxMDc06lkQxrrXiFLfo5R46b9ahbtOVRBPMGWNKtRTeUjY0MQZw5Sr4toBNSXDZtV3ut91KLnbG67clVL-Cn3pbIN8C0bzDn6__GX4DXyaEvA</recordid><startdate>20170701</startdate><enddate>20170701</enddate><creator>Isiten, Havva Nuket</creator><creator>Cebi, Merve</creator><creator>Sutcubasi Kaya, Bernis</creator><creator>Metin, Baris</creator><creator>Tarhan, Nevzat</creator><general>SAGE Publications</general><general>SAGE PUBLICATIONS, INC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20170701</creationdate><title>Medication Effects on EEG Biomarkers in Attention-Deficit/Hyperactivity Disorder</title><author>Isiten, Havva Nuket ; Cebi, Merve ; Sutcubasi Kaya, Bernis ; Metin, Baris ; Tarhan, Nevzat</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c431t-aa04f1288e7fa4a4707779dc358c7a99f841d2a844e5f6720a5fd9e5660335273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adolescent</topic><topic>Antidepressive Agents - administration & dosage</topic><topic>Attention Deficit Disorder with Hyperactivity - diagnosis</topic><topic>Attention Deficit Disorder with Hyperactivity - drug therapy</topic><topic>Attention Deficit Disorder with Hyperactivity - physiopathology</topic><topic>Attention deficit hyperactivity disorder</topic><topic>Bioindicators</topic><topic>Biomarkers</topic><topic>Brain</topic><topic>Brain Waves - drug effects</topic><topic>Central Nervous System Stimulants - administration & dosage</topic><topic>Child</topic><topic>Children</topic><topic>Comorbidity</topic><topic>Dextroamphetamine - administration & dosage</topic><topic>Dopamine</topic><topic>Dopamine Antagonists - administration & dosage</topic><topic>Drug Monitoring</topic><topic>EEG</topic><topic>Electroencephalography</topic><topic>Electroencephalography - drug effects</topic><topic>Electroencephalography - methods</topic><topic>Female</topic><topic>Humans</topic><topic>Hyperactivity</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Methylphenidate</topic><topic>Methylphenidate - administration & dosage</topic><topic>Neurosciences</topic><topic>Observer Variation</topic><topic>Psychiatry</topic><topic>Reproducibility of Results</topic><topic>Retrospective Studies</topic><topic>Sensitivity and Specificity</topic><topic>Studies</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Isiten, Havva Nuket</creatorcontrib><creatorcontrib>Cebi, Merve</creatorcontrib><creatorcontrib>Sutcubasi Kaya, Bernis</creatorcontrib><creatorcontrib>Metin, Baris</creatorcontrib><creatorcontrib>Tarhan, Nevzat</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical EEG and neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Isiten, Havva Nuket</au><au>Cebi, Merve</au><au>Sutcubasi Kaya, Bernis</au><au>Metin, Baris</au><au>Tarhan, Nevzat</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Medication Effects on EEG Biomarkers in Attention-Deficit/Hyperactivity Disorder</atitle><jtitle>Clinical EEG and neuroscience</jtitle><addtitle>Clin EEG Neurosci</addtitle><date>2017-07-01</date><risdate>2017</risdate><volume>48</volume><issue>4</issue><spage>246</spage><epage>250</epage><pages>246-250</pages><issn>1550-0594</issn><eissn>2169-5202</eissn><abstract>EEG biomarkers have become increasingly used to aid in diagnosis of attention-deficit/hyperactivity disorder (ADHD). Despite several studies suggesting that EEG theta/beta ratio may help discriminating ADHD from other disorders, the effect of medications on theta/beta ratio is not known. Forty-three children with ADHD that were evaluated with quantitative EEG before and after methylphenidate were included in the study. Theta/beta ratio, theta and beta powers for whole brain, central, and frontal areas were calculated. Theta/beta power decreased significantly after treatment; however, this change was largely due to an increase in beta power, rather than a fall in theta power. The results suggest that beta power is sensitive to medication effects, while theta power remains as a trait biomarker unaffected by medication status. The value of EEG biomarkers for monitoring neuropsychological performance and clinical status should be explored by future studies.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>27798290</pmid><doi>10.1177/1550059416675232</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1550-0594 |
| ispartof | Clinical EEG and neuroscience, 2017-07, Vol.48 (4), p.246-250 |
| issn | 1550-0594 2169-5202 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1834998420 |
| source | MEDLINE; SAGE Complete |
| subjects | Adolescent Antidepressive Agents - administration & dosage Attention Deficit Disorder with Hyperactivity - diagnosis Attention Deficit Disorder with Hyperactivity - drug therapy Attention Deficit Disorder with Hyperactivity - physiopathology Attention deficit hyperactivity disorder Bioindicators Biomarkers Brain Brain Waves - drug effects Central Nervous System Stimulants - administration & dosage Child Children Comorbidity Dextroamphetamine - administration & dosage Dopamine Dopamine Antagonists - administration & dosage Drug Monitoring EEG Electroencephalography Electroencephalography - drug effects Electroencephalography - methods Female Humans Hyperactivity Male Medical imaging Methylphenidate Methylphenidate - administration & dosage Neurosciences Observer Variation Psychiatry Reproducibility of Results Retrospective Studies Sensitivity and Specificity Studies Treatment Outcome |
| title | Medication Effects on EEG Biomarkers in Attention-Deficit/Hyperactivity Disorder |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T19%3A17%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Medication%20Effects%20on%20EEG%20Biomarkers%20in%20Attention-Deficit/Hyperactivity%20Disorder&rft.jtitle=Clinical%20EEG%20and%20neuroscience&rft.au=Isiten,%20Havva%20Nuket&rft.date=2017-07-01&rft.volume=48&rft.issue=4&rft.spage=246&rft.epage=250&rft.pages=246-250&rft.issn=1550-0594&rft.eissn=2169-5202&rft_id=info:doi/10.1177/1550059416675232&rft_dat=%3Cproquest_cross%3E1910433388%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1910433388&rft_id=info:pmid/27798290&rft_sage_id=10.1177_1550059416675232&rfr_iscdi=true |